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ABSTRACT 
Drug Utilization Study of Bevacizumab in Patients with                  
Retinopathy of Prematurity 
(Study at SMF Ilmu Kesehatan Mata                                                         
General Hospital Dr. Soetomo Surabaya) 
 
Lim Shaoqin 
 
Retinopathy of prematurity (ROP), a retinal vascular disease of 
premature infants is becoming one of the leading causes of childhood 
blindness. In ROP neovascularization occurs due to retinal immature and 
primarily caused by VEGF. One of the therapy for ROP therapy is anti-VEGF 
where bevacizumab is the most used in General Hospital Dr. Soetomo. 
Bevacizumab binds to VEGF and inhibits the binding of VEGF molecules to 
their receptors on the surface of vascular endothelial cells. Therefore, 
inhibition of VEGF activity may inhibits abnormal angiogenesis in retinal. 
The study aims is to describe the utilization of bevacizumab and its therapy 
outcome in ROP patients at General Hospital Dr. Soetomo. Data were 
obtained retrospectively and prospectively observational using time limited 
sampling method within period 1st January 2015 - 30th April 2018. 35 eyes of 
20 patients (11 male and 9 female) were included in the study. Most patients 
were 36 and 38 weeks gestational age when receiving bevacizumab therapy. 
The main risk factors in ROP patients are low gestational age (90.0 %), low 
birth weight (60.0 %), and followed by oxygen therapy (55.0 %). Patients 
with ROP stage III+ (76.0 %) were the most diagnosed ROP receiving 
bevacizumab injection. The dosage used for intravitreal injection of 
bevacizumab in ROP patients is 0.625 mg/ 0.025 mL for once during 
hospitalization. 88.0 % eyes shown positive results while 6.0 % eyes worsen 
after bevacizumab injection. In conclusion, these results are in accordance 
with the BEAT-ROP where bevacizumab 0.625 mg/ 0.025 mL is effective in 
treating ROP with plus disease. 
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